Welcome to Scrip
Create an account to read this article
Already a subscriber?
Sanofi-Aventis China R&D Head Frank Jiang On Fast And Furious Adaptation In China: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis is grabbing a larger share of emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down with PharmAsia News to discuss the environment in China and how Sanofi is approaching R&D there. Jiang is also a member of the networking organization BayHelix, which links Chinese life sciences executives.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.
• By
The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.
• By
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.